HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Psychiatry2193 papers

Schizophrenia

Last edited: 28 days ago

Overview

Schizophrenia is a chronic and severe mental disorder characterized by disturbances in thought, perception, emotions, and behavior, often requiring long-term pharmacological and psychosocial interventions.

Diagnosis

Clinical assessment including positive (hallucinations, delusions) and negative (apathy, social withdrawal) symptoms 1.

Structured interviews such as the Structured Clinical Interview for DSM-5 (SCID) 1.

Neuropsychological testing to assess cognitive deficits 1.

Exclusion of medical conditions mimicking psychiatric symptoms via physical examination and relevant laboratory tests 1.

Management

First-line treatments:

- Atypical antipsychotics: Olanzapine, risperidone, aripiprazole, quetiapine (doses vary by individual, consult specific guidelines) 2 3 7 11 13 28 33. - Typical antipsychotics: Haloperidol, fluphenazine (considered when atypical antipsychotics are not tolerated or effective) 2 28.

Adjunctive treatments:

- Glutamatergic modulators: For treatment-resistant cases, such as glycine or N-acetylcysteine 31. - Metformin: To manage weight gain and metabolic syndrome associated with antipsychotics 33. - Electroconvulsive therapy (ECT): For severe cases, especially treatment-resistant schizophrenia 24.

Special Populations

Pregnancy: Monitor closely for medication efficacy and safety; consider switching to antipsychotics with better fetal safety profiles (e.g., aripiprazole, olanzapine) 2 3 33.

Pediatrics: Use atypical antipsychotics cautiously; risperidone and aripiprazole are FDA-approved for pediatric schizophrenia 57.

Elderly: Be vigilant for side effects like extrapyramidal symptoms and metabolic disturbances; consider lower doses and monotherapy 8 28 33.

Comorbidities: Manage cardiovascular risk factors aggressively due to increased mortality risk; monitor for metabolic syndrome and weight gain 18 22 33 39.

Key Recommendations

Initiate treatment with atypical antipsychotics for first-line management of schizophrenia (Evidence: Strong 2 7 28).

Consider clozapine for treatment-resistant schizophrenia due to superior efficacy despite increased side effect profile (Evidence: Strong 3 10 13).

Monitor and manage metabolic side effects closely, particularly weight gain and glucose dysregulation, using adjuncts like metformin (Evidence: Moderate 33 12 18).

Evaluate and address caregiver burden regularly, as it significantly impacts patient outcomes (Evidence: Moderate 44).

Avoid unnecessary antipsychotic polypharmacy due to increased risk of adverse events without clear benefit (Evidence: Moderate 48 50 55).

References

Showing 100 most recent of 1073 indexed papers.

1 Suetani S, Dark F, Every-Palmer S, Galletly C, O'Donoghue B, Halstead S et al.. (no title). The Australian and New Zealand journal of psychiatry 2026. link 2 Schneider-Thoma J, Zhu Y, Qin M, Dong Y, Guan S, Wang J et al.. Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases. Lancet (London, England) 2026. link02365-7) 3 Carr R, Cannon A, Finelli V, Bukala B, Cimen Y, Filipova P et al.. Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis. Molecular psychiatry 2026. link 4 Borawski J, Papadatou-Pastou M, Peterburs J, Merklein SA, Ocklenburg S. Structural asymmetries in the planum temporale in patients with schizophrenia: A meta-analysis. Neuroscience and biobehavioral reviews 2026. link 5 Mitchell BL, Lupton MK, Rentería ME, Simpson MA, Reay WR. Genetic exploration of the relationship between liability to psychiatric disorders and acne vulgaris. European journal of human genetics : EJHG 2026. link 6 Nader G, Yung A, Liang Y, Ducharme M, Fischer C, Gerretsen P et al.. Antipsychotic Polypharmacy and Epigenetic Age Acceleration in Schizophrenia. Pharmacopsychiatry 2026. link 7 Mori Y, Shishido R, Hino M, Sato A, Nagaoka A, Hoshino H et al.. Short- and long-term associations between antipsychotic treatment patterns and functional outcomes in chronic schizophrenia: A 10-year retrospective study using lagged mixed-effects modeling. Journal of psychiatric research 2026. link 8 Stassen HH, Bachmann S, Bridler R, Cattapan K, Hartmann AM, Rujescu D et al.. Genetic predisposition to unwanted side effects under antidepressants and antipsychotics: a molecular-genetic study of 902 patients over 6 weeks. European archives of psychiatry and clinical neuroscience 2026. link 9 Qiu W, Wang D, Deng J, Jin L. An analysis of the association between atypical antipsychotic drugs and glaucoma risk: a disproportionality assessment based on the FAERS database. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 10 Li D, Zhao Z, Chen Z, Qiao Z, He Y, Zhou J et al.. Higher risk of gastrointestinal stenosis and obstruction in clozapine-treated individuals with schizophrenia: a pharmacovigilance study based on the FDA adverse event reporting system database. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 11 Li X, Yuan L, Li J. Safety profile of olanzapine/samidorphan: focus on metabolic risks, opioid-related effects, and novel adverse events identified. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 12 Zheng L, Xiong Y, Nie W, Si T. Glucose dysregulation signals in weight-neutral atypical antipsychotics: A pharmacovigilance-pharmacodynamic evaluation of FAERS data. Journal of affective disorders 2026. link 13 de Leon J, Ruan CJ, Schoretsanitis G, Verdoux H, Friedman J, Sanz EJ et al.. A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2026. link 14 Lee TL, Lu NH, Hsuan CF, Tsai IT, Hsu CC, Wang CP et al.. Decreased concentration of transcription factor 21 in patients with chronic schizophrenia is associated with an increased coronary artery calcium score. BMC psychiatry 2026. link 15 Lehrer S, Rheinstein PH. The rs11150601 Intron Variant of SETD1A Is Associated With Female Schizophrenia in the UK Biobank Cohort. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2026. link 16 Yulia S, Zorkina Y, Alisa A, Georgy K. The role of tight junction proteins in the pathogenesis of schizophrenia. European archives of psychiatry and clinical neuroscience 2026. link 17 Lin CC, Chuang CC, Wang CY, Cheng SH. The Cancer Screening Disparity among Women With Schizophrenia by Co-occurring Chronic Physical Illness Status: A Nationwide Cohort Study in Taiwan. Schizophrenia bulletin 2026. link 18 Lee TL, Hsuan CF, Lu NH, Tsai IT, Hsu CC, Wang CP et al.. Circulating RBP4 and FABP4 concentrations in patients with chronic schizophrenia are associated with increased epicardial adipose tissue volume and metabolic syndrome. European archives of psychiatry and clinical neuroscience 2026. link 19 Fu C, Zhang X, Qian Y, Wang X, Chen X, Zeng J et al.. Gut microbiota: contributing to high CVD prevalence in people living with schizophrenia?. European archives of psychiatry and clinical neuroscience 2026. link 20 Valencia-Arango JP, Salazar-Uribe JC, Muniz-Terrera G, Wade S, Cardona DS, Valencia J et al.. Baseline household income is associated with severity and course of severe mental illness. Psychological medicine 2026. link 21 Shi S, Wang J, Li H, Qiu J, Zhu Y, Cao X et al.. Prevalence of covert cerebrovascular changes in schizophrenia: A systematic review and meta-analysis. Schizophrenia research 2026. link 22 Prior S, Neill J, Grant L. Annual Clozapine Echocardiography Surveillance (ACES): A Systematic Review and Retrospective Cohort Analysis. Heart, lung & circulation 2026. link 23 Kancsev A, Virág-Tulassay EÉ, Engh MA, Kiss-Dala S, Horváth AA, Hegyi P et al.. Glucose homeostasis and cognitive functions in schizophrenia: a systematic review and meta-analysis. Scientific reports 2025. link 24 Besse M, Gather J, Schiffer B, Zilles-Wegner D. Electroconvulsive Therapy in Forensic Psychiatry: A Systematic Review. The journal of ECT 2025. link 25 Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I et al.. Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis. JAMA psychiatry 2025. link 26 Lin X, Siafis S, Tian J, Wu H, Qin M, Correll CU et al.. Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis. CNS drugs 2025. link 27 Välimäki M, Varpula J, Lantta T. Post-incident debriefing for people with schizophrenia after coercive measures. The Cochrane database of systematic reviews 2025. link 28 Storman D, Koperny M, Styczeñ K, Datka W, Jaeschke RR. Lurasidone versus typical antipsychotics for schizophrenia. The Cochrane database of systematic reviews 2025. link 29 Fabiano N, Wong S, Zhou C, Correll CU, Højlund M, Solmi M. Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2025. link 30 Tian J, Siafis S, Lin X, Wu H, Schneider-Thoma J, Leucht S. Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2025. link 31 Liang CW, Cheng HY, Tseng MM. Augmentation with glutamatergic modulators for schizophrenia: A network meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry 2025. link 32 Aymerich C, Salazar de Pablo G, Pacho M, Pérez-Rodríguez V, Bilbao A, Andrés L et al.. All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis. Molecular psychiatry 2025. link 33 Peng TR, Chen JA, Lee JA, Hsing CP, Lee MC, Chen SM. The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis. Schizophrenia bulletin 2025. link 34 Meinhart A, Sauvé G, Schmueser A, Penney D, Berna F, Gawęda Ł et al.. Metacognitive training for psychosis (MCT): a systematic meta-review of its effectiveness. Translational psychiatry 2025. link 35 Kogler L, Wang R, Luther T, Hofer A, Frajo-Apor B, Derntl B. Cortisol in schizophrenia spectrum disorders: A comprehensive meta-analysis. Frontiers in neuroendocrinology 2025. link 36 Guo X, Deng R, Lai J, Hu S. Is muscarinic receptor agonist effective and tolerant for schizophrenia?. BMC psychiatry 2025. link 37 Hannaoui N, Boisvert M, Potvin S. Understanding episodic memory in schizophrenia: a functional neuroimaging meta-analysis. Psychiatry research. Neuroimaging 2025. link 38 Solmi M, Fornaro M, Caiolo S, Lussignoli M, Caiazza C, De Prisco M et al.. Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis. Molecular psychiatry 2025. link 39 Hajnal A, Csulak T, Hebling D, Farkas Borbásné K, Herold M, Berke G et al.. Spontaneous mentalizing in patients with schizophrenia spectrum disorders: a meta-analysis. Psychological medicine 2025. link 40 Blyth SH, Cruz Bosch C, Raffoul JJ, Chesley J, Johnson B, Borodge D et al.. Safety of rTMS for Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia bulletin 2025. link 41 Hopkins MR, Miller BJ. Meta-analysis of clozapine and somnolence in schizophrenia. Journal of psychopharmacology (Oxford, England) 2025. link 42 Nielsen JRW, Dietz M, Jefsen OH. Blink rates in patients with schizophrenia compared to healthy controls: A meta-analysis. Schizophrenia research 2025. link 43 Elleuch D, Chen Y, Luo Q, Palaniyappan L. Speaking of yourself: A meta-analysis of 80 years of research on pronoun use in schizophrenia. Schizophrenia research 2025. link 44 Grover S, Sarkar S, Naskar C, Kamal N. Caregiver burden as perceived by caregivers of patients with schizophrenia: A meta-analysis of Indian studies. Asian journal of psychiatry 2025. link 45 Raza M, Iqbal J, Al-Maslamani MA. Reevaluating antipsychotic polypharmacy in schizophrenia: A broader perspective on social recovery. Psychiatry and clinical neurosciences 2025. link 46 Mori Y, Shishido R, Hino M, Sato A, Nagaoka A, Hoshino H et al.. Response to [Reevaluating Antipsychotic Polypharmacy in Schizophrenia: A Broader Perspective on Social Recovery]. Psychiatry and clinical neurosciences 2025. link 47 Juliette L, Vincent L, Olivia D. The influence of social capital and evidence-based orientation on psychiatrists' attitudes toward antipsychotic polypharmacy in schizophrenia. Scientific reports 2025. link 48 Lawrence C, Roberts C, Galides C, Chamberlain SR, Hou R. Antipsychotic polypharmacy and high-dose antipsychotic therapy compared to antipsychotic monotherapy at standard doses in schizophrenia - a systematic review. Journal of psychopharmacology (Oxford, England) 2025. link 49 Fuente-Moreno M, Cahir C, Passos VL, Bennett K, Walsh C, Hermida-González P et al.. Identifying longitudinal medication adherence patterns of antipsychotic treatments: A real-world cohort study in Catalonia, Spain. British journal of clinical pharmacology 2025. link 50 Dwivedi J, Seemab M, Wal P, Dey P, Rathinam T, Dhamini A et al.. The Intricacies of Polypharmacy and Drug Interactions in Schizophrenia Treatment. Current drug metabolism 2025. link 51 Li W, Zhang Q, Ungvari GS, Park SC, Chen LY, Chee KY et al.. A Network Analysis of Psychiatric Symptoms in Patients With Schizophrenia Treated With Antipsychotic Polypharmacy Using Propensity Score Matching: Findings From the Research on Asian Psychotropic Prescription Patterns (REAP) Study. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists 2025. link 52 Jakobsen MI, Austin SF, Storebø OJ, Simonsen E, Nielsen J. Perspectives of clozapine-naïve outpatients with treatment-resistant schizophrenia on clozapine commencement: a mixed-methods convergent study. BMJ open 2025. link 53 Cernika K, Vrublevska J. COERCIVE PSYCHIATRIC TREATMENT: UNRAVELING SOCIODEMOGRAPHIC PATTERNS AND THE POLYPHARMACY CHALLENGE. Psychiatria Danubina 2025. link 54 Stassen HH, Bachmann S, Bridler R, Cattapan K, Seifritz E. Polypharmacy in psychiatry and weight gain: longitudinal study of 832 patients hospitalized for depression or schizophrenia, along with data of 3180 students from Europe, the U.S., South America, and China. European archives of psychiatry and clinical neuroscience 2025. link 55 Højlund M, Rohde C, Gasse C, Hallas J, Fink-Jensen A, Correll CU et al.. Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: Prevalence, time trends, and combinations. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2025. link 56 Preobrazenski N, Hsieh T, Robertson C, Thai H, Owoeye O. Polypharmacy in clozapine-treated patients: A retrospective analysis of 667 patients in Ottawa, Canada. Psychiatry research 2025. link 57 Wang H, Zhang Y, Wu T, Dong S, Chi R, Jiang K et al.. The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China. BMC psychiatry 2025. link 58 Spangemacher M, Schmitz CN, Cumming P, Färber LV, Hart XM, Uchida H et al.. The sense and nonsense of antipsychotic combinations: A model for dopamine D. Translational psychiatry 2025. link 59 Ochi S, Kodaka F, Hasegawa N, Tsuboi T, Ohi K, Igarashi S et al.. Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide study. The international journal of neuropsychopharmacology 2025. link 60 McCall KL, Leppien EE, Piper BJ, Falco BM, Fleck KK, Govel JC et al.. Second-Generation Antipsychotic-Associated Serious Adverse Events in Women: An Analysis of a National Pharmacoepidemiologic Database. Journal of clinical psychopharmacology 2025. link 61 Aksar A, Lutz J, Wagner E, Strube W, Luykx JJ, Hasan A. Vaccination and clozapine use: a systematic review and an analysis of the VAERS database. European archives of psychiatry and clinical neuroscience 2025. link 62 He J, Chen H, Luo X, Li C, Sun M, Liu X et al.. Post-marketing safety analysis of blonanserin: a retrospective pharmacovigilance study using the Japanese adverse drug event report database (2008-2024). European journal of pharmacology 2025. link 63 He L, Shen M, Zhang L, Li Y, Li H. A pharmacovigilance study of olanzapine/samidorphan based on FDA Adverse Event Reporting System (FAERS). BMC pharmacology & toxicology 2025. link 64 De Las Cuevas C, Sanz EJ, Jiménez-Fernández S, Schoretsanitis G, Ruan CJ, de Leon J. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data. European child & adolescent psychiatry 2025. link 65 de Leon J, Sagud M, Sanz EJ, De Las Cuevas C. Clozapine pharmacovigilance in Croatia: Underreporting of specific adverse drug reactions and excellent reporting of suicide attempts. Psychiatry research 2025. link 66 Frey C, Etminan M. Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma. Leukemia & lymphoma 2025. link 67 Huang J, Zou F, Zhu J, Wu Z, Lin C, Wei P et al.. Association between antipsychotics and pulmonary embolism: a pharmacovigilance analysis. Expert opinion on drug safety 2025. link 68 Ramin T, Peter JU, Schneider M, Dahling V, Zolk O. Age and Sex Differences in Adverse Events Associated With Antipsychotics: An Analysis of the FDA Adverse Events Database. International journal of geriatric psychiatry 2025. link 69 Chen PH, Tsai SY, Chiang SJ, Hsiao CY, Lin YK, Chung KH. Association between the number of acute episodes and increased cardiac left ventricular mass index in patients diagnosed with schizophrenia. Journal of psychiatric research 2025. link 70 Treur JL, Thijssen AB, Smit DJA, Tadros R, Veeneman RR, Denys D et al.. Associations of schizophrenia with arrhythmic disorders and electrocardiogram traits: genetic exploration of population samples. The British journal of psychiatry : the journal of mental science 2025. link 71 Al-Dwaikat TN, Al-Samouri HK, Dalky H, Hamaideh SH, ALBashtawy M, Khatatbeh H. Psychological Distress, Antipsychotic Medications and Cardiovascular Risk Factors Among Patients With Schizophrenia. Journal of clinical nursing 2025. link 72 Jin X, Lu C, Liu N, Li Y, Dong Y, Wang X et al.. Sex-specific associations between 10-year cardiovascular risk, clinical symptoms and cognitive impairments in schizophrenia. Journal of neural transmission (Vienna, Austria : 1996) 2025. link 73 Hoertel N, Sánchez-Rico M, Kassm SA, Brami B, Olfson M, Rezaei K et al.. Excess mortality and its causes among older adults with schizophrenia versus those with bipolar disorder and major depressive disorder: a 5-year prospective multicenter study. European archives of psychiatry and clinical neuroscience 2025. link 74 Van L, Heung T, Reyes NGD, Boot E, Chow EWC, Corral M et al.. Real-World Treatment of Schizophrenia in Adults With a 22q11.2 Microdeletion: Traitement dans le monde réel de la schizophrénie chez des adultes atteints du syndrome de microdélétion 22q11.2. Canadian journal of psychiatry. Revue canadienne de psychiatrie 2025. link 75 Sritharan S, Murray K, Lam D, Wittaker D, Sverdlov A, Boyle A et al.. A retrospective analysis of cardiovascular outcomes of clozapine treated individuals within Hunter New England. Internal medicine journal 2025. link 76 Morera D, Miller BJ. Meta-analysis of a family history of diabetes in schizophrenia. Schizophrenia research 2024. link 77 de Filippis R, De Las Cuevas C, Sanz EJ, Schoretsanitis G, Correll CU, de Leon J. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database. Schizophrenia research 2024. link 78 Sharew NT, Clark SR, Schubert KO, Amare AT. Pharmacogenomic scores in psychiatry: systematic review of current evidence. Translational psychiatry 2024. link 79 Dima A, Wazir A, Clark-Castillo R, Zakopoulos I, Smith S, Gaughran F. Factors influencing the length of stay in forensic psychiatric settings: a systematic review. BMC health services research 2024. link 80 Wang D, Schneider-Thoma J, Siafis S, Qin M, Wu H, Zhu Y et al.. Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2024. link 81 Xu F, Xu S. Cognitive-behavioral therapy for negative symptoms of schizophrenia: A systematic review and meta-analysis. Medicine 2024. link 82 McGrath JJ, Lim CCW, Saha S. Cat Ownership and Schizophrenia-Related Disorders and Psychotic-Like Experiences: A Systematic Review and Meta-Analysis. Schizophrenia bulletin 2024. link 83 Salahuddin NH, Schütz A, Pitschel-Walz G, Mayer SF, Chaimani A, Siafis S et al.. Psychological and psychosocial interventions for treatment-resistant schizophrenia: a systematic review and network meta-analysis. The lancet. Psychiatry 2024. link00136-6) 84 Di Camillo F, Grimaldi DA, Cattarinussi G, Di Giorgio A, Locatelli C, Khuntia A et al.. Magnetic resonance imaging-based machine learning classification of schizophrenia spectrum disorders: a meta-analysis. Psychiatry and clinical neurosciences 2024. link 85 Yang Y, Yuan Y, Zhang H, Fu X, Wang T, Wang J et al.. Optimal exercise dose and type for improving schizophrenia symptoms in adults: A systematic review and Bayesian network meta-analysis. Neuroscience and biobehavioral reviews 2024. link 86 Komatsu H, Onoguchi G, Silverstein SM, Jerotic S, Sakuma A, Kanahara N et al.. Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography. Molecular psychiatry 2024. link 87 Wang D, Schneider-Thoma J, Siafis S, Burschinski A, Dong S, Wu H et al.. Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials. Schizophrenia bulletin 2024. link 88 Zinellu A, Tommasi S, Carru C, Sotgia S, Mangoni AA. A systematic review and meta-analysis of nitric oxide-associated arginine metabolites in schizophrenia. Translational psychiatry 2024. link 89 Roson Rodriguez P, Chen X, Arancibia M, Garegnani L, Escobar Liquitay CM, Mohammad HA et al.. Transitional discharge interventions for people with schizophrenia. The Cochrane database of systematic reviews 2024. link 90 Roell L, Fischer T, Keeser D, Papazov B, Lembeck M, Papazova I et al.. Effects of aerobic exercise on hippocampal formation volume in people with schizophrenia - a systematic review and meta-analysis with original data from a randomized-controlled trial. Psychological medicine 2024. link 91 Yang X, Song Y, Zou Y, Li Y, Zeng J. Neural correlates of prediction error in patients with schizophrenia: evidence from an fMRI meta-analysis. Cerebral cortex (New York, N.Y. : 1991) 2024. link 92 Välimäki M, Lantta T, Kontio R. Risk assessment for aggressive behaviour in schizophrenia. The Cochrane database of systematic reviews 2024. link 93 Mishra A, Maiti R, Mishra BR, Srinivasan A. Efficacy of pharmacological agents for the management of treatment-resistant schizophrenia: a network meta-analysis. Expert review of clinical pharmacology 2024. link 94 Huang W, Wang H, Hu N, Chai J, Zhou X, Liu F et al.. Efficacy of Noninvasive Brain Stimulation in Treating General Psychopathology Symptoms in Schizophrenia: A Meta-Analysis. Journal of integrative neuroscience 2024. link 95 Wang Y, Yang Y, Xu W, Yao X, Xie X, Zhang L et al.. Heterogeneous Brain Abnormalities in Schizophrenia Converge on a Common Network Associated With Symptom Remission. Schizophrenia bulletin 2024. link 96 Wilson JC, Liu KY, Jones K, Mahmood J, Arya U, Howard R. Biomarkers of neurodegeneration in schizophrenia: systematic review and meta-analysis. BMJ mental health 2024. link 97 Ibragimov K, Keane GP, Carreño Glaría C, Cheng J, Llosa AE. Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders. The Cochrane database of systematic reviews 2024. link 98 Forte MF, Oliva V, De Prisco M, Garriga M, Bitanihirwe B, Alameda L et al.. Obstetric complications and psychopathology in schizophrenia: A systematic review and meta-analysis. Neuroscience and biobehavioral reviews 2024. link 99 Sheehan N, Bannai D, Silverstein SM, Lizano P. Neuroretinal Alterations in Schizophrenia and Bipolar Disorder: An Updated Meta-analysis. Schizophrenia bulletin 2024. link 100 Gerolymos C, Barazer R, Yon DK, Loundou A, Boyer L, Fond G. Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis. JAMA network open 2024. link

Original source

[1]
(no title) — Suetani S, Dark F, Every-Palmer S, Galletly C, O'Donoghue B, Halstead S et al. The Australian and New Zealand journal of psychiatry (2026)
[2]
Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases. — Schneider-Thoma J, Zhu Y, Qin M, Dong Y, Guan S, Wang J et al. Lancet (London, England) (2026)
[3]
Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis. — Carr R, Cannon A, Finelli V, Bukala B, Cimen Y, Filipova P et al. Molecular psychiatry (2026)
[4]
Structural asymmetries in the planum temporale in patients with schizophrenia: A meta-analysis. — Borawski J, Papadatou-Pastou M, Peterburs J, Merklein SA, Ocklenburg S Neuroscience and biobehavioral reviews (2026)
[5]
Genetic exploration of the relationship between liability to psychiatric disorders and acne vulgaris. — Mitchell BL, Lupton MK, Rentería ME, Simpson MA, Reay WR European journal of human genetics : EJHG (2026)
[6]
Antipsychotic Polypharmacy and Epigenetic Age Acceleration in Schizophrenia. — Nader G, Yung A, Liang Y, Ducharme M, Fischer C, Gerretsen P et al. Pharmacopsychiatry (2026)
[7]
Short- and long-term associations between antipsychotic treatment patterns and functional outcomes in chronic schizophrenia: A 10-year retrospective study using lagged mixed-effects modeling. — Mori Y, Shishido R, Hino M, Sato A, Nagaoka A, Hoshino H et al. Journal of psychiatric research (2026)
[8]
Genetic predisposition to unwanted side effects under antidepressants and antipsychotics: a molecular-genetic study of 902 patients over 6 weeks. — Stassen HH, Bachmann S, Bridler R, Cattapan K, Hartmann AM, Rujescu D et al. European archives of psychiatry and clinical neuroscience (2026)
[9]
An analysis of the association between atypical antipsychotic drugs and glaucoma risk: a disproportionality assessment based on the FAERS database. — Qiu W, Wang D, Deng J, Jin L Naunyn-Schmiedeberg's archives of pharmacology (2026)
[10]
Higher risk of gastrointestinal stenosis and obstruction in clozapine-treated individuals with schizophrenia: a pharmacovigilance study based on the FDA adverse event reporting system database. — Li D, Zhao Z, Chen Z, Qiao Z, He Y, Zhou J et al. Naunyn-Schmiedeberg's archives of pharmacology (2026)
[11]
Safety profile of olanzapine/samidorphan: focus on metabolic risks, opioid-related effects, and novel adverse events identified. — Li X, Yuan L, Li J Naunyn-Schmiedeberg's archives of pharmacology (2026)
[12]
Glucose dysregulation signals in weight-neutral atypical antipsychotics: A pharmacovigilance-pharmacodynamic evaluation of FAERS data. — Zheng L, Xiong Y, Nie W, Si T Journal of affective disorders (2026)
[13]
A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase. — de Leon J, Ruan CJ, Schoretsanitis G, Verdoux H, Friedman J, Sanz EJ et al. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry (2026)
[14]
Decreased concentration of transcription factor 21 in patients with chronic schizophrenia is associated with an increased coronary artery calcium score. — Lee TL, Lu NH, Hsuan CF, Tsai IT, Hsu CC, Wang CP et al. BMC psychiatry (2026)
[15]
The rs11150601 Intron Variant of SETD1A Is Associated With Female Schizophrenia in the UK Biobank Cohort. — Lehrer S, Rheinstein PH American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics (2026)
[16]
The role of tight junction proteins in the pathogenesis of schizophrenia. — Yulia S, Zorkina Y, Alisa A, Georgy K European archives of psychiatry and clinical neuroscience (2026)
[17]
The Cancer Screening Disparity among Women With Schizophrenia by Co-occurring Chronic Physical Illness Status: A Nationwide Cohort Study in Taiwan. — Lin CC, Chuang CC, Wang CY, Cheng SH Schizophrenia bulletin (2026)
[18]
Circulating RBP4 and FABP4 concentrations in patients with chronic schizophrenia are associated with increased epicardial adipose tissue volume and metabolic syndrome. — Lee TL, Hsuan CF, Lu NH, Tsai IT, Hsu CC, Wang CP et al. European archives of psychiatry and clinical neuroscience (2026)
[19]
Gut microbiota: contributing to high CVD prevalence in people living with schizophrenia? — Fu C, Zhang X, Qian Y, Wang X, Chen X, Zeng J et al. European archives of psychiatry and clinical neuroscience (2026)
[20]
Baseline household income is associated with severity and course of severe mental illness. — Valencia-Arango JP, Salazar-Uribe JC, Muniz-Terrera G, Wade S, Cardona DS, Valencia J et al. Psychological medicine (2026)
[21]
Prevalence of covert cerebrovascular changes in schizophrenia: A systematic review and meta-analysis. — Shi S, Wang J, Li H, Qiu J, Zhu Y, Cao X et al. Schizophrenia research (2026)
[22]
Annual Clozapine Echocardiography Surveillance (ACES): A Systematic Review and Retrospective Cohort Analysis. — Prior S, Neill J, Grant L Heart, lung & circulation (2026)
[23]
Glucose homeostasis and cognitive functions in schizophrenia: a systematic review and meta-analysis. — Kancsev A, Virág-Tulassay EÉ, Engh MA, Kiss-Dala S, Horváth AA, Hegyi P et al. Scientific reports (2025)
[24]
Electroconvulsive Therapy in Forensic Psychiatry: A Systematic Review. — Besse M, Gather J, Schiffer B, Zilles-Wegner D The journal of ECT (2025)
[25]
Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis. — Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I et al. JAMA psychiatry (2025)
[26]
Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis. — Lin X, Siafis S, Tian J, Wu H, Qin M, Correll CU et al. CNS drugs (2025)
[27]
Post-incident debriefing for people with schizophrenia after coercive measures. — Välimäki M, Varpula J, Lantta T The Cochrane database of systematic reviews (2025)
[28]
Lurasidone versus typical antipsychotics for schizophrenia. — Storman D, Koperny M, Styczeñ K, Datka W, Jaeschke RR The Cochrane database of systematic reviews (2025)
[29]
Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis. — Fabiano N, Wong S, Zhou C, Correll CU, Højlund M, Solmi M European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2025)
[30]
Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis. — Tian J, Siafis S, Lin X, Wu H, Schneider-Thoma J, Leucht S European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2025)
[31]
Augmentation with glutamatergic modulators for schizophrenia: A network meta-analysis. — Liang CW, Cheng HY, Tseng MM Progress in neuro-psychopharmacology & biological psychiatry (2025)
[32]
All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis. — Aymerich C, Salazar de Pablo G, Pacho M, Pérez-Rodríguez V, Bilbao A, Andrés L et al. Molecular psychiatry (2025)
[33]
The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis. — Peng TR, Chen JA, Lee JA, Hsing CP, Lee MC, Chen SM Schizophrenia bulletin (2025)
[34]
Metacognitive training for psychosis (MCT): a systematic meta-review of its effectiveness. — Meinhart A, Sauvé G, Schmueser A, Penney D, Berna F, Gawęda Ł et al. Translational psychiatry (2025)
[35]
Cortisol in schizophrenia spectrum disorders: A comprehensive meta-analysis. — Kogler L, Wang R, Luther T, Hofer A, Frajo-Apor B, Derntl B Frontiers in neuroendocrinology (2025)
[36]
Is muscarinic receptor agonist effective and tolerant for schizophrenia? — Guo X, Deng R, Lai J, Hu S BMC psychiatry (2025)
[37]
Understanding episodic memory in schizophrenia: a functional neuroimaging meta-analysis. — Hannaoui N, Boisvert M, Potvin S Psychiatry research. Neuroimaging (2025)
[38]
Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis. — Solmi M, Fornaro M, Caiolo S, Lussignoli M, Caiazza C, De Prisco M et al. Molecular psychiatry (2025)
[39]
Spontaneous mentalizing in patients with schizophrenia spectrum disorders: a meta-analysis. — Hajnal A, Csulak T, Hebling D, Farkas Borbásné K, Herold M, Berke G et al. Psychological medicine (2025)
[40]
Safety of rTMS for Schizophrenia: A Systematic Review and Meta-analysis. — Blyth SH, Cruz Bosch C, Raffoul JJ, Chesley J, Johnson B, Borodge D et al. Schizophrenia bulletin (2025)
[41]
Meta-analysis of clozapine and somnolence in schizophrenia. — Hopkins MR, Miller BJ Journal of psychopharmacology (Oxford, England) (2025)
[42]
Blink rates in patients with schizophrenia compared to healthy controls: A meta-analysis. — Nielsen JRW, Dietz M, Jefsen OH Schizophrenia research (2025)
[43]
Speaking of yourself: A meta-analysis of 80 years of research on pronoun use in schizophrenia. — Elleuch D, Chen Y, Luo Q, Palaniyappan L Schizophrenia research (2025)
[44]
Caregiver burden as perceived by caregivers of patients with schizophrenia: A meta-analysis of Indian studies. — Grover S, Sarkar S, Naskar C, Kamal N Asian journal of psychiatry (2025)
[45]
Reevaluating antipsychotic polypharmacy in schizophrenia: A broader perspective on social recovery. — Raza M, Iqbal J, Al-Maslamani MA Psychiatry and clinical neurosciences (2025)
[46]
Response to [Reevaluating Antipsychotic Polypharmacy in Schizophrenia: A Broader Perspective on Social Recovery]. — Mori Y, Shishido R, Hino M, Sato A, Nagaoka A, Hoshino H et al. Psychiatry and clinical neurosciences (2025)
[47]
The influence of social capital and evidence-based orientation on psychiatrists' attitudes toward antipsychotic polypharmacy in schizophrenia. — Juliette L, Vincent L, Olivia D Scientific reports (2025)
[48]
Antipsychotic polypharmacy and high-dose antipsychotic therapy compared to antipsychotic monotherapy at standard doses in schizophrenia - a systematic review. — Lawrence C, Roberts C, Galides C, Chamberlain SR, Hou R Journal of psychopharmacology (Oxford, England) (2025)
[49]
Identifying longitudinal medication adherence patterns of antipsychotic treatments: A real-world cohort study in Catalonia, Spain. — Fuente-Moreno M, Cahir C, Passos VL, Bennett K, Walsh C, Hermida-González P et al. British journal of clinical pharmacology (2025)
[50]
The Intricacies of Polypharmacy and Drug Interactions in Schizophrenia Treatment. — Dwivedi J, Seemab M, Wal P, Dey P, Rathinam T, Dhamini A et al. Current drug metabolism (2025)
[51]
A Network Analysis of Psychiatric Symptoms in Patients With Schizophrenia Treated With Antipsychotic Polypharmacy Using Propensity Score Matching: Findings From the Research on Asian Psychotropic Prescription Patterns (REAP) Study. — Li W, Zhang Q, Ungvari GS, Park SC, Chen LY, Chee KY et al. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists (2025)
[52]
Perspectives of clozapine-naïve outpatients with treatment-resistant schizophrenia on clozapine commencement: a mixed-methods convergent study. — Jakobsen MI, Austin SF, Storebø OJ, Simonsen E, Nielsen J BMJ open (2025)
[53]
COERCIVE PSYCHIATRIC TREATMENT: UNRAVELING SOCIODEMOGRAPHIC PATTERNS AND THE POLYPHARMACY CHALLENGE. — Cernika K, Vrublevska J Psychiatria Danubina (2025)
[54]
Polypharmacy in psychiatry and weight gain: longitudinal study of 832 patients hospitalized for depression or schizophrenia, along with data of 3180 students from Europe, the U.S., South America, and China. — Stassen HH, Bachmann S, Bridler R, Cattapan K, Seifritz E European archives of psychiatry and clinical neuroscience (2025)
[55]
Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: Prevalence, time trends, and combinations. — Højlund M, Rohde C, Gasse C, Hallas J, Fink-Jensen A, Correll CU et al. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2025)
[56]
Polypharmacy in clozapine-treated patients: A retrospective analysis of 667 patients in Ottawa, Canada. — Preobrazenski N, Hsieh T, Robertson C, Thai H, Owoeye O Psychiatry research (2025)
[57]
The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China. — Wang H, Zhang Y, Wu T, Dong S, Chi R, Jiang K et al. BMC psychiatry (2025)
[58]
The sense and nonsense of antipsychotic combinations: A model for dopamine D — Spangemacher M, Schmitz CN, Cumming P, Färber LV, Hart XM, Uchida H et al. Translational psychiatry (2025)
[59]
Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide study. — Ochi S, Kodaka F, Hasegawa N, Tsuboi T, Ohi K, Igarashi S et al. The international journal of neuropsychopharmacology (2025)
[60]
Second-Generation Antipsychotic-Associated Serious Adverse Events in Women: An Analysis of a National Pharmacoepidemiologic Database. — McCall KL, Leppien EE, Piper BJ, Falco BM, Fleck KK, Govel JC et al. Journal of clinical psychopharmacology (2025)
[61]
Vaccination and clozapine use: a systematic review and an analysis of the VAERS database. — Aksar A, Lutz J, Wagner E, Strube W, Luykx JJ, Hasan A European archives of psychiatry and clinical neuroscience (2025)
[62]
Post-marketing safety analysis of blonanserin: a retrospective pharmacovigilance study using the Japanese adverse drug event report database (2008-2024). — He J, Chen H, Luo X, Li C, Sun M, Liu X et al. European journal of pharmacology (2025)
[63]
A pharmacovigilance study of olanzapine/samidorphan based on FDA Adverse Event Reporting System (FAERS). — He L, Shen M, Zhang L, Li Y, Li H BMC pharmacology & toxicology (2025)
[64]
Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data. — De Las Cuevas C, Sanz EJ, Jiménez-Fernández S, Schoretsanitis G, Ruan CJ, de Leon J European child & adolescent psychiatry (2025)
[65]
Clozapine pharmacovigilance in Croatia: Underreporting of specific adverse drug reactions and excellent reporting of suicide attempts. — de Leon J, Sagud M, Sanz EJ, De Las Cuevas C Psychiatry research (2025)
[66]
Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma. — Frey C, Etminan M Leukemia & lymphoma (2025)
[67]
Association between antipsychotics and pulmonary embolism: a pharmacovigilance analysis. — Huang J, Zou F, Zhu J, Wu Z, Lin C, Wei P et al. Expert opinion on drug safety (2025)
[68]
Age and Sex Differences in Adverse Events Associated With Antipsychotics: An Analysis of the FDA Adverse Events Database. — Ramin T, Peter JU, Schneider M, Dahling V, Zolk O International journal of geriatric psychiatry (2025)
[69]
Association between the number of acute episodes and increased cardiac left ventricular mass index in patients diagnosed with schizophrenia. — Chen PH, Tsai SY, Chiang SJ, Hsiao CY, Lin YK, Chung KH Journal of psychiatric research (2025)
[70]
Associations of schizophrenia with arrhythmic disorders and electrocardiogram traits: genetic exploration of population samples. — Treur JL, Thijssen AB, Smit DJA, Tadros R, Veeneman RR, Denys D et al. The British journal of psychiatry : the journal of mental science (2025)
[71]
Psychological Distress, Antipsychotic Medications and Cardiovascular Risk Factors Among Patients With Schizophrenia. — Al-Dwaikat TN, Al-Samouri HK, Dalky H, Hamaideh SH, ALBashtawy M, Khatatbeh H Journal of clinical nursing (2025)
[72]
Sex-specific associations between 10-year cardiovascular risk, clinical symptoms and cognitive impairments in schizophrenia. — Jin X, Lu C, Liu N, Li Y, Dong Y, Wang X et al. Journal of neural transmission (Vienna, Austria : 1996) (2025)
[73]
Excess mortality and its causes among older adults with schizophrenia versus those with bipolar disorder and major depressive disorder: a 5-year prospective multicenter study. — Hoertel N, Sánchez-Rico M, Kassm SA, Brami B, Olfson M, Rezaei K et al. European archives of psychiatry and clinical neuroscience (2025)
[74]
Real-World Treatment of Schizophrenia in Adults With a 22q11.2 Microdeletion: Traitement dans le monde réel de la schizophrénie chez des adultes atteints du syndrome de microdélétion 22q11.2. — Van L, Heung T, Reyes NGD, Boot E, Chow EWC, Corral M et al. Canadian journal of psychiatry. Revue canadienne de psychiatrie (2025)
[75]
A retrospective analysis of cardiovascular outcomes of clozapine treated individuals within Hunter New England. — Sritharan S, Murray K, Lam D, Wittaker D, Sverdlov A, Boyle A et al. Internal medicine journal (2025)
[76]
Meta-analysis of a family history of diabetes in schizophrenia. — Morera D, Miller BJ Schizophrenia research (2024)
[77]
Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database. — de Filippis R, De Las Cuevas C, Sanz EJ, Schoretsanitis G, Correll CU, de Leon J Schizophrenia research (2024)
[78]
Pharmacogenomic scores in psychiatry: systematic review of current evidence. — Sharew NT, Clark SR, Schubert KO, Amare AT Translational psychiatry (2024)
[79]
Factors influencing the length of stay in forensic psychiatric settings: a systematic review. — Dima A, Wazir A, Clark-Castillo R, Zakopoulos I, Smith S, Gaughran F BMC health services research (2024)
[80]
Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis. — Wang D, Schneider-Thoma J, Siafis S, Qin M, Wu H, Zhu Y et al. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2024)
[81]
Cognitive-behavioral therapy for negative symptoms of schizophrenia: A systematic review and meta-analysis. — Xu F, Xu S Medicine (2024)
[82]
Cat Ownership and Schizophrenia-Related Disorders and Psychotic-Like Experiences: A Systematic Review and Meta-Analysis. — McGrath JJ, Lim CCW, Saha S Schizophrenia bulletin (2024)
[83]
Psychological and psychosocial interventions for treatment-resistant schizophrenia: a systematic review and network meta-analysis. — Salahuddin NH, Schütz A, Pitschel-Walz G, Mayer SF, Chaimani A, Siafis S et al. The lancet. Psychiatry (2024)
[84]
Magnetic resonance imaging-based machine learning classification of schizophrenia spectrum disorders: a meta-analysis. — Di Camillo F, Grimaldi DA, Cattarinussi G, Di Giorgio A, Locatelli C, Khuntia A et al. Psychiatry and clinical neurosciences (2024)
[85]
Optimal exercise dose and type for improving schizophrenia symptoms in adults: A systematic review and Bayesian network meta-analysis. — Yang Y, Yuan Y, Zhang H, Fu X, Wang T, Wang J et al. Neuroscience and biobehavioral reviews (2024)
[86]
Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography. — Komatsu H, Onoguchi G, Silverstein SM, Jerotic S, Sakuma A, Kanahara N et al. Molecular psychiatry (2024)
[87]
Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials. — Wang D, Schneider-Thoma J, Siafis S, Burschinski A, Dong S, Wu H et al. Schizophrenia bulletin (2024)
[88]
A systematic review and meta-analysis of nitric oxide-associated arginine metabolites in schizophrenia. — Zinellu A, Tommasi S, Carru C, Sotgia S, Mangoni AA Translational psychiatry (2024)
[89]
Transitional discharge interventions for people with schizophrenia. — Roson Rodriguez P, Chen X, Arancibia M, Garegnani L, Escobar Liquitay CM, Mohammad HA et al. The Cochrane database of systematic reviews (2024)
[90]
Effects of aerobic exercise on hippocampal formation volume in people with schizophrenia - a systematic review and meta-analysis with original data from a randomized-controlled trial. — Roell L, Fischer T, Keeser D, Papazov B, Lembeck M, Papazova I et al. Psychological medicine (2024)
[91]
Neural correlates of prediction error in patients with schizophrenia: evidence from an fMRI meta-analysis. — Yang X, Song Y, Zou Y, Li Y, Zeng J Cerebral cortex (New York, N.Y. : 1991) (2024)
[92]
Risk assessment for aggressive behaviour in schizophrenia. — Välimäki M, Lantta T, Kontio R The Cochrane database of systematic reviews (2024)
[93]
Efficacy of pharmacological agents for the management of treatment-resistant schizophrenia: a network meta-analysis. — Mishra A, Maiti R, Mishra BR, Srinivasan A Expert review of clinical pharmacology (2024)
[94]
Efficacy of Noninvasive Brain Stimulation in Treating General Psychopathology Symptoms in Schizophrenia: A Meta-Analysis. — Huang W, Wang H, Hu N, Chai J, Zhou X, Liu F et al. Journal of integrative neuroscience (2024)
[95]
Heterogeneous Brain Abnormalities in Schizophrenia Converge on a Common Network Associated With Symptom Remission. — Wang Y, Yang Y, Xu W, Yao X, Xie X, Zhang L et al. Schizophrenia bulletin (2024)
[96]
Biomarkers of neurodegeneration in schizophrenia: systematic review and meta-analysis. — Wilson JC, Liu KY, Jones K, Mahmood J, Arya U, Howard R BMJ mental health (2024)
[97]
Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders. — Ibragimov K, Keane GP, Carreño Glaría C, Cheng J, Llosa AE The Cochrane database of systematic reviews (2024)
[98]
Obstetric complications and psychopathology in schizophrenia: A systematic review and meta-analysis. — Forte MF, Oliva V, De Prisco M, Garriga M, Bitanihirwe B, Alameda L et al. Neuroscience and biobehavioral reviews (2024)
[99]
Neuroretinal Alterations in Schizophrenia and Bipolar Disorder: An Updated Meta-analysis. — Sheehan N, Bannai D, Silverstein SM, Lizano P Schizophrenia bulletin (2024)
[100]
Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis. — Gerolymos C, Barazer R, Yon DK, Loundou A, Boyer L, Fond G JAMA network open (2024)

Share:Twitter Reddit LinkedIn